Mount Sinai Hospital

Mikra Announces Joint Product with Jose Bautista

Retrieved on: 
星期一, 五月 6, 2024
Caffeine, Brain, FOCUS, Animal, Cognition, Research, Nutrient, Human, Phenylalanine, Science, MLB, Pleasure, Tyrosine, Memory, Crash, Neuron, Olympic, Mount Sinai Hospital, Regeneration, Sleep, Systematic review, Dietary supplement

Mikra’s new product FOCUS combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver superior clarity of cognition and improved memory without any caffeine or stimulants.

Key Points: 
  • Mikra’s new product FOCUS combines a precision blend of citicoline, tyrosine and pure lion's mane mushroom to deliver superior clarity of cognition and improved memory without any caffeine or stimulants.
  • We deeply appreciate his contributions as an elite athlete with unique insights into achieving peak human performance.
  • “It’s been a blast working with Team Mikra on developing FOCUS,” said Jose Bautista.
  • “It is an absolute pleasure to be collaborating with Jose Bautista to develop FOCUS, leveraging his experience both as an accomplished entrepreneur and as an elite athlete with extensive firsthand knowledge of cutting-edge nutraceutical supplementation.

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

Retrieved on: 
星期一, 五月 6, 2024
Research fellow, Metabolism, Economics, AstraZeneca, Biomedical sciences, Inflammation, Princeton University, GSK plc, Roche, Mount Sinai Hospital, Harvard Medical School, Form 6-K, Phi Beta Kappa, Therapy, Physician, Columbia University, IPO, Perella Weinberg Partners, Former, Wellesley College, Stanford University, Business development, Stem cell, Neoplasm, Columbia Business School, Pharmaceutical industry

The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.

Key Points: 
  • The new members of the Board include: John L. Cantello, Ph.D., Lauren H. Chung, Ph.D., Armon R. Sharei, Ph.D. and Todd Wider, M.D., and Pierluigi Paracchi, Chief Executive Officer, will continue to serve on the Board as Chairman.
  • "When Luigi Naldini, Ph.D., M.D., and I co-founded Genenta, we always aspired to involve leading figures in the biotech sector.
  • Previously, Lauren co-founded Tokum Capital Management, a global institutional healthcare fund, and successfully managed its merger with Perella Weinberg Partners.
  • Todd is also a principal in Wider Film Projects, a documentary film company focused on producing films with sociopolitical resonance that have won Academy, Emmy and Peabody Awards.

Kardium Announces Enhanced Clinical Capabilities of the Globe® System With Right Atrial Ablation and Hybrid Energy Ablation

Retrieved on: 
星期四, 五月 9, 2024
Cardiology, Other Health, Health, General Health, Pharmaceutical, Health Technology, Other Science, Medical Devices, Research, Hospitals, Science, Electrode, American College, AFL, Heart, CTI, Arrhythmia, Gold, Atrial flutter, Patient, RF, Mount Sinai Hospital, PVI, Inc., Atrial fibrillation, Catheter, Incidence, Medical imaging

The ablation procedures were also completed utilizing pulsed field (PF) energy, radiofrequency (RF) energy, or a hybrid combination of both, all using sedation without the need for general anesthesia.

Key Points: 
  • The ablation procedures were also completed utilizing pulsed field (PF) energy, radiofrequency (RF) energy, or a hybrid combination of both, all using sedation without the need for general anesthesia.
  • Atrial flutter, the second most common cardiac arrhythmia after atrial fibrillation, frequently accompanies atrial fibrillation.1 In the United States, about 200,000 new cases of atrial flutter arise each year, 2 with CTI-line ablation being the preferred approach to prevent atrial flutter occurrences.
  • Dr. Vivek Reddy of The Mount Sinai Hospital, New York, remarked, “Treating CTI-dependent atrial flutter with the Globe System showcases a differentiating approach in ablation catheter technology.
  • Kardium Inc. ( kardium.com ) is a rapidly growing, privately held medical solutions company that has developed an advanced system for atrial fibrillation (AF) treatment: the Globe® System.

DR. KIYA MOVASSAGHI ASSUMES PRESIDENCY OF THE AESTHETIC SOCIETY, CHARTING A COURSE FOR GLOBAL PARTNERSHIPS AND ADVANCING AESTHETIC EDUCATION

Retrieved on: 
星期日, 五月 5, 2024
Education, General surgery, Breast, Resident, Weight loss, Partnership, NYU, University, Face, Rhinoplasty, Woman, DMD, Large, Abdominoplasty, Navy, Executive Committee, Memorandum, Mount Sinai Hospital, Harvard Medical School, Fifth Avenue, Emory University, Royal college, Microsoft, Safety, Publication, Plastic surgery, Division, The Hamptons, School, Society, Patient, Medical school, University Health Network, Elective surgery, FACS, Annual general meeting, Massachusetts General Hospital, Women's College Hospital, Dentistry

VANCOUVER, BC, May 5, 2024 /PRNewswire/ -- The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The Society's position as the global leader in education and innovation in the aesthetic marketplace.

Key Points: 
  • Dr. Movassaghi's leadership will focus on strategically fortifying The Society's position as the global leader in education and innovation in the aesthetic marketplace.
  • "I am honored to assume the presidency of The Aesthetic Society," said Dr. Movassaghi.
  • Global outreach through Memorandums of Understanding (MOUs) will be instrumental in shaping our engagement and alliances among our international colleagues.
  • A 1995 graduate of Harvard Medical School, Dr. Movassaghi completed a three-year plastic surgery residency at the Harvard Combined Plastic Surgery Program.

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
星期一, 四月 15, 2024
American Academy, University, Participation, MD, Publication, Patient, RMS, AAN, USF, Mount Sinai Hospital, Multiple sclerosis, Therapy, Pharmaceutical industry

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.

Key Points: 
  • NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado.
  • A link to the data presented yesterday is included below.
  • Two additional presentations will be shared on Wednesday April 17, 2024.
  • Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated “The ULTIMATE I & II Phase 3 trials demonstrated robust clinical activity for BRIUMVI compared to teriflunomide and these post-hoc analyses provide interesting new insights and support BRIUMVI’s utility as an important treatment option for patients with relapsing forms of multiple sclerosis.

Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study

Retrieved on: 
星期二, 四月 2, 2024
Software, Hardware, Medical Devices, Technology, Health Technology, Clinical Trials, Surgery, Nanotechnology, Cardiology, Biotechnology, FDA, Health, Inc., Atrial fibrillation, Patient, Gold, PFA, McGill University Health Centre, IDE, Electrode, Workflow, Heart, PMA, Safety, Patient safety, Multimedia, Mount Sinai Hospital, Food, Medical device

Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.

Key Points: 
  • Kardium Inc. , a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study.
  • (Photo: Business Wire)
    The PULSAR IDE study, an international, multi-center clinical trial, is designed to evaluate the safety and effectiveness of the Globe System for the treatment of atrial fibrillation.
  • The successful completion of enrollment underscores the commitment of the clinical sites, investigators, and the entire Kardium team.
  • "The completion of enrollment in the PULSAR study represents a major accomplishment for Kardium.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
星期二, 三月 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center to host international conference on complex cardiac arrhythmias

Retrieved on: 
星期二, 三月 26, 2024
Arrhythmia, American Medical Association, St Davids, University of Pennsylvania, Mount Sinai Hospital, MedStar Health, Patient, PFA, Electrophysiology, University, LAA, Medical Center, Cleveland Clinic, Atrial fibrillation, Ventricular tachycardia, Physician, Cardiac electrophysiology, Vancouver General Hospital, PRA

AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.

Key Points: 
  • AUSTIN, Texas, March 26, 2024 /PRNewswire/ -- On April 18 and 19, 2024, the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center will host its seventh international symposium on complex arrhythmias, EPLive 2024.
  • Live cases, which are broadcast with expert commentary from the state-of-the-art Electrophysiology Center at St. David's Medical Center, will serve as the primary teaching tool.
  • The Texas Cardiac Arrhythmia Institute features the leading robotic electrophysiology center in North America.
  • The 72,000-square-foot center, which opened in 2019, includes six electrophysiology labs equipped with advanced technology for treatment of complex arrhythmias.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
星期二, 三月 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Retrieved on: 
星期五, 三月 8, 2024
American Academy of Neurology, MD, Mount Sinai Hospital, USF, Multiple sclerosis, AAN, Abstract (summary), University, Therapy, Patient, RMS, Publication, American Academy, Harbor

NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.

Key Points: 
  • NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the upcoming American Academy of Neurology 2024 annual meeting, being held April 13 - 18, 2024, in Dever, Colorado.
  • Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/msa/Public/Events/Index/49 .
  • Details of the upcoming presentations are outlined below.
  • Lead Author: Stephen Krieger, MD - The Corinne Goldsmith Dickinson Center for MS, The Mount Sinai Hospital NY, NY
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Lead Author: Derrick Robertson, MD - University of South Florida (USF) Morsani College of Medicine in Tampa, Florida
    Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm .